vx984
vx984 Basic information
- Product Name:
- vx984
- Synonyms:
-
- vx984
- vx-984
- VX-984 (Synonyms: M9831)
- VX-984 (M9831)
- (S)-N-Methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl-4',6'-d2)amino)propan-2-yl)quinoline-4-carboxamide
- M9831 free base
- VX984,VX 984
- VX-984, 10 mM in DMSO
- CAS:
- 1476074-39-1
- MF:
- C23H23N7O
- MW:
- 413.49
- Mol File:
- 1476074-39-1.mol
vx984 Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- DMSO : 8.33 mg/mL (20.05 mM)
- form
- Solid
- color
- White to off-white
vx984 Usage And Synthesis
Uses
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium[1][2][3].
in vivo
VX-984 (0-100 mg/kg, Oral gavage, daily) inhibits radiation-induced DNA-PKcs phosphorylation in orthotopic brain tumor xenografts[1].
VX-984 (0-50 mg/kg, Oral gavage, twice a day for 2 days) enhances the radiosensitivity of brain tumor xenografts[1].
| Animal Model: | Athymic female nude mice (6-8 weeks old, 7-8 mice/group, U251 intracerebral xenografts)[1] |
| Dosage: | 0, 50, and 100 mg/kg |
| Administration: | Oral gavage, daily, 1 or 4 hours before irradiation (10 Gy) |
| Result: | Reduced the levels DNA-PKcs phosphorylation after irradiation. |
| Animal Model: | Athymic female nude mice (6-8 weeks old, 7 mice/group, U251 intracerebral xenografts)[1] |
| Dosage: | 0, 50 mg/kg |
| Administration: | Oral gavage, twice a day, 30 minutes before and 4 hours following local irradiation of the tumor (3 Gy) for 3 consecutive days (3×3 Gy) |
| Result: | VX-984 treatment of U251 tumors alone had no significant effect on overall survival as compared with vehicle; radiation alone resulted in an increase in survival. VX-984 and radiation combination protocol increased tumor radiosensitivity, and significantly increased the survival of mice compared with radiation alone. |
References
[1] Timme CR, et al. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts. Mol Cancer Ther. 2018 Jun;17(6):1207-1216. DOI:10.1158/1535-7163.MCT-17-1267
[2] Khan AJ, et al. VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells. Oncotarget. 2018 May 25;9(40):25833-25841. DOI:10.18632/oncotarget.25383
[3] Diane Boucher, et al. Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC. Cancer Res (2016) 76 (14_Supplement): 3716.
[4] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
vx984Supplier
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Tel
- 028-67271278 18628360895
- sales@artisbio.com
- Tel
- 021-65675885 18964387627
- info@efebio.com
- Tel
- +86 18721201413
- sales@biopharmaleader.com
- Tel
- 15911056312
- liming@bio-fount.com